Navigation Links
Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
Date:1/28/2009

LONDON, January 28 /PRNewswire/ -- Immune Targeting Systems (ITS) Limited, a company developing synthetic vaccines for mutating viruses, today announced it has received GBP2.4m of investment as the second tranche of its series-A funding round. ITS's investors HealthCap, the London Technology Fund, Novartis Venture Fund & Truffle Capital provided additional funding to enable a seamless transition into the clinic for the company's universal flu vaccine program which has now entered the GMP pre-clinical phase.

Simultaneously ITS has moved to strengthen its board and management team with the appointment of Brenda Reynolds, a co-founder of PowderMed (acquired by Pfizer in 2006), as company director. Another seasoned vaccine industry professional, Jill Makin, former VP of R&D for Emergent Biosolutions and Microscience, also joins in a consultancy capacity and is responsible for the GMP vaccine manufacture and its release to the clinic.

ITS CEO Carlton Brown commented: "Brenda and Jill are valuable additions to the team and will help drive both our clinical and commercial programs forward. The second tranche of investment brings our total funding to more than GBP5m, including a GBP0.5m development grant from the London Development Agency. We are aiming to raise series-B investment in 2009 to fund our universal influenza vaccine clinical program to proof-of-concept and bring other prioritized candidates through the pipeline. We expect to commence the clinical program by the end of 2009. Despite the current economic climate, our research tells us that the market remains strong for both a successful universal influenza vaccine and therapeutic T-cell vaccine platform."

    Corporate Inquiries
    Carlton Brown; Chief Executive Officer
    Tel +44-7970-944-454, +44-20-7691-4908
    Email: carlton.brown@its-innovation.co.uk


'/>"/>
SOURCE Immune Targeting Systems (ITS) Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Innovative Beverage Products Launches New Product Designed to Enhance the Bodys Immune Defense
2. Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimers Disease Drug Development
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
5. IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant
6. MedImmune Announces Zook as President
7. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
8. Visualizing asthma-causing immune cells at work
9. Protein-printing technique gives snapshots of immune system defense
10. Peptimmune Presentations at Upcoming Events
11. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... Winston-Salem, NC (PRWEB) , ... February 23, 2017 , ... ... pleased to announce a new partnership with Compass Research . GGI's mission is ... gifting a vaccine to a child in need in honor of each clinical trial ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
Breaking Biology News(10 mins):